Imatinib for the Treatment of COVID-19 in Hospitalized Adults

Inclusion Criteria

• Ability to understand and willingness to sign a written informed consent document. Informed consent must be obtained prior to participation in the study. For patients who are too unwell to provide consent such as patients on invasive ventilator or extracorporeal membrane oxygenation (ECMO), legally authorized representative (LAR) can sign the informed consent
• Hospitalized patients ≥ 18 years of age
• Positive reverse transcription polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 in the respiratory tract sample (oropharyngeal, nasopharyngeal or bronchoalveolar lavage [BAL]) by Center for Disease Control or local laboratory within 7 days of randomization
• Women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study

Exclusion Criteria

• Patients receiving any other investigational agents in a clinical trial. Off-label use of agents such as hydroxychloroquine is not an exclusion criterion
• Pregnant or breastfeeding women
• Direct bilirubin > 2.5 mg/dL (at screen)
• Alanine aminotransferase (ALT) > 5 x upper limit of normal (at screen)
• Absolute neutrophil count (ANC) < 200/uL (at screen)
• Platelet < 20,000/uL (at screen)
• Hemoglobin < 7 g/dL (at screen)
• Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator’s judgment would limit compliance with study requirements
• Known allergy to imatinib or its component products
• Any other clinical conditions that in the opinion of the investigator would make the subject unsuitable for the study